Abstract: In accordance with various embodiments of the disclosed subject matter, a system, device and platform for culturing and maintaining tissue representative cellular models combined with active fluidics mimicking body circulation. In combination, multiple chamber devices enable modeling of multi-organ communication, representative of in vivo conditions.

Abstract: The present disclosure provides metalloporphyrin and metallochlorin compounds (e.g., compounds of Formula (II) and (III)), which are useful in the preparation of optical devices (e.g., contact lenses, intraocular lenses, implantable contact lenses) that protect retinal pigment epithelium by the selective blocking of blue light. Also provided are precursor porphyrin and chlorin compounds (e.g., compounds of Formula (I)), and compositions and optical devices incorporating the compounds of the disclosure. Also provided are methods of selecting appropriate metalloporphyrin and metallochlorin compounds for incorporation into optical devices wherein the devices mitigate damage to retinal epithelial cells while balancing changes to luminous transmission, discomfort glare, color distortion, and disruption of circadian rhythms.

Abstract: A method for modulating RNA with tetracycline compounds is described.

Abstract: A method for enhanced safety and/or training compliance in computer systems is described. In one embodiment, the method includes generating a user interface to enable configuration of an in-person event, selecting a location for the in-person event, selecting a range threshold for the selected location of the in-person event, and determining whether a first attendee attended or is attending the in-person event based at least in part on a location of the first attendee relative to the location of the in-person event.

Abstract: A method for improving safety and/or training compliance computer systems is described. In one embodiment, the method includes generating a safety rating of an entity, generating a safety rating of a person associated with the entity, detecting a safety compliance action of the person, updating the safety rating of the person based at least in part on the detected safety compliance action, and updating the safety rating of the entity based at least in part on the updating of the safety rating of the person. In some cases, the entity includes a corporation, a partnership, a company, an organization, an institution, or any group of people, or any combination thereof.

Abstract: A method for improving safety and/or training compliance computer systems is described. In one embodiment, the method includes analyzing a plurality of incidents in real time based at least in part on one or more incident criteria; identifying an incident trend among at least one of the one or more incident criteria analyzed; analyzing a training history of at least a first organization that is associated with the incident trend; analyzing a training history of a second organization; and using machine learning to predict a future occurrence of an incident associated with the incident trend based at least in part on the analysis of the training history of the second organization.

Abstract: Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: A method for modulating RNA with tetracycline compounds is described.

Abstract: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: 11a,12-dehydrotetracycline compounds are described.

Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: A method for modulating RNA with tetracycline compounds is described.

Abstract: Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.

Abstract: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: A method for modulating RNA with tetracycline compounds is described.

Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.